Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Jeffrey Graham\textsuperscript{a}, J. Connor Wells\textsuperscript{a}, Frede Donskov\textsuperscript{b}, Jae Lyun Lee\textsuperscript{c}, Anna Fraccon\textsuperscript{d}, Felice Pasini\textsuperscript{e}, Camillo Porta\textsuperscript{f}, I. Alex Bowman\textsuperscript{g}, Georg A. Bjarnason\textsuperscript{h}, D. Scott Ernst\textsuperscript{i}, Sun Young Rha\textsuperscript{j}, Benoit Beuselinck\textsuperscript{k}, Aaron Hansen\textsuperscript{l}, Scott A. North\textsuperscript{m}, Christian K. Kollmannsberger\textsuperscript{n}, Lori A. Wood\textsuperscript{o}, Ulka N. Vaishampayan\textsuperscript{p}, Sumanta K. Pal\textsuperscript{q}, Toni K. Choueiri\textsuperscript{r,1}, Daniel Y.C. Heng\textsuperscript{a,1,*}

\textsuperscript{a}Tom Baker Cancer Centre, University of Calgary, Calgary, Canada
\textsuperscript{b}Aarhus University Hospital, Aarhus, Denmark
\textsuperscript{c}University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
\textsuperscript{d}CDC Pererzoli, Peschiera del Garda, Italy
\textsuperscript{e}Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy
\textsuperscript{f}University of Pavia, Pavia, Italy
\textsuperscript{g}UT Southwestern Medical Center, Dallas, TX, USA
\textsuperscript{h}Sunnybrook Research Institute, Toronto, Canada
\textsuperscript{i}London Health Sciences Centre, London, Canada
\textsuperscript{j}Yonsei University College of Medicine, Seoul, Republic of Korea
\textsuperscript{k}University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
\textsuperscript{l}Princess Margaret Cancer Centre, Toronto, Canada
\textsuperscript{m}University of Alberta, Cross Cancer Institute, Edmonton, Canada
\textsuperscript{n}British Columbia Cancer Agency, Vancouver, Canada

\textsuperscript{*}Corresponding author. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 29th Street NW, Calgary T2N 4N2, Canada. Tel.: +1 403 6717750., daniel.heng@ahs.ca (Daniel Y.C. Heng).

\textsuperscript{1}These authors contributed equally to this work.

\textbf{Author contributions:} Daniel Y.C. Heng had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

\textit{Study concept and design:} All authors.

\textit{Acquisition of data:} All authors.

\textit{Analysis and interpretation of data:} Heng, Graham.

\textit{Drafting of the manuscript:} Heng, Graham.

\textit{Critical revision of the manuscript for important intellectual content:} All authors.

\textit{Statistical analysis:} Heng, Graham.

\textit{Obtaining funding:} None.

\textit{Administrative, technical, or material support:} Heng, Graham.

\textit{Supervision:} Heng.

\textit{Other:} None.
Abstract

Background: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, with more limited data on the role of CN in patients with papillary histology.

Objective: To determine the benefit of CN in synchronous metastatic papillary RCC.

Design, setting, and participants: Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, a retrospective analysis was performed for patients with papillary mRCC treated with or without CN.

Outcome measurements and statistical analysis: Median overall survival (OS) and progression-free survival (PFS) were determined for both patient groups. Cox regression analysis was performed to control for imbalances in individual IMDC risk factors.

Results and limitations: In total, 647 patients with papillary mRCC were identified, of whom 353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 were not. The median follow-up was 57.1 mo (95% confidence interval [CI] 32.9–77.8) and the OS from the start of first-line targeted therapy for the entire cohort was 13.2 mo (95% CI 12.0–16.1). Median OS for patients with CN was 16.3 mo, compared to 8.6 mo (p < 0.0001) in the no-CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN was 0.62 (95% CI 0.45–0.85; p = 0.0031). Limitations include the retrospective nature of the analysis.

Conclusions: The use of CN in patients with mRCC and papillary histology appears to be associated with better survival compared to no CN after adjustment for risk criteria. Selection of appropriate candidates for CN is crucial. A clinical trial in this rare population may not be possible.

Patient summary: In a population of patients with advanced papillary kidney cancer, we found that surgical removal of the primary kidney tumor was associated with better overall survival.

Keywords
Kidney cancer; Metastatic renal cell carcinoma; Papillary; Cytoreductive nephrectomy

1. Introduction

Despite impressive advances in treatment, renal cell carcinoma (RCC) remains a significant global health issue, with approximately 30% of patients presenting with advanced disease [1]. The treatment landscape for metastatic RCC (mRCC) has undergone a dramatic transformation in recent years because of the introduction of molecularly targeted therapies.
and novel immuno-oncology (IO) agents [2]. Despite these therapeutic advances, the management of mRCC still requires a multimodal approach, with the incorporation of systemic targeted and IO therapies, as well as selected use of radiation therapy and surgical interventions.

The evidence for surgical resection of the primary renal tumor in synchronous metastatic disease is derived from both observational studies and randomized trials. Evidence supporting the use of cytoreductive nephrectomy (CN) comes from data from prospective trials in the era of IFN therapy, as well as retrospective studies performed in the more modern, targeted therapy era. A pooled analysis of two prospective randomized clinical trials demonstrated that CN followed by IFN treatment was associated with a 5.8-mo increase in overall survival (OS) when compared to IFN alone (13.6 vs 7.8 mo) [3]. Similarly, retrospective analyses of real-world mRCC data sets have also suggested a survival benefit from CN among patients treated with targeted therapy [4,5]. By contrast, the recently reported phase 3 CARMENA clinical trial demonstrated that targeted therapy with sunitinib alone was noninferior to nephrectomy followed by sunitinib in International mRCC Database Consortium (IMDC) intermediate- and poor-risk patients with clear cell histology [6]. In general, the potential benefits of CN must be balanced carefully with the possible complications and morbidity of this procedure.

The majority of these studies have focused primarily on clear cell RCC (ccRCC), the most common RCC histological subtype. There are more limited data regarding the role of CN in non–clear-cell RCC (nccRCC). Within nccRCC pathology, the most common subtype is papillary RCC, accounting for approximately 10–15% of RCC cases. Papillary RCC has unique biological and clinical features compared to traditional ccRCC histology [7]. This includes more frequent genetic mutations in MET and FH, rather than the VHL alterations seen in ccRCC. Clinically, papillary RCC is characterized by diverse outcomes, with both indolent and aggressive tumors. Thus, the role of CN in papillary RCC may differ when compared to its ccRCC counterpart. Given this context, this study was designed to determine the benefit of CN in synchronous metastatic papillary RCC using the IMDC database.

2. Patients and methods

2.1. Patient population

Patient data were collected retrospectively from 38 international cancer centers included in the IMDC. The IMDC is a large, multi-institutional set comprising data for patients with metastatic RCC [8]. Inclusion criteria for this study were patients with metastatic RCC and papillary histology. We further divided this cohort into patients treated with targeted therapy without a history of nephrectomy, and those treated with CN, defined as nephrectomy performed after diagnosis of synchronous metastatic disease or within 90 d before diagnosis of metastatic disease [5].

Data were collected using uniform database software and templates. Baseline demographic, clinical, and laboratory data were collected, including variables found to have prognostic significance. Laboratory values were standardized against their respective institution upper limit of normal (ULN) and lower limit of normal (LLN) values as necessary. Outcomes
measured included (OS), progression free survival (PFS), and objective response rate (ORR) to first-line therapy. The data included patients accrued between 2005 and October 2017. This study received institutional review board approval from each participating center.

2.2. Statistical analysis

The primary outcome of this study was OS, defined as time from initiation of first-line targeted therapy to the date of death or censored at last follow-up. A secondary outcome was PFS, defined as time from initiation of targeted therapy to the date of progression, drug cessation, or censored at last follow-up. Median OS and PFS distributions were estimated using the Kaplan-Meier method. Cox proportional hazards regression was used to determine hazard ratios (HRs) after adjustment for baseline prognostic variables. This included adjusting for the IMDC prognostic factors: hemoglobin below the LLN, corrected calcium greater than the ULN, neutrophils above the ULN, platelets greater than the ULN, Karnofsky performance status (KPS) <80%, and time from diagnosis to treatment of <1 yr. The IMDC prognostic factors have been validated in metastatic papillary RCC [9]. Adjusted HRs and corresponding p values are reported. Statistical analyses were performed with SAS v.9.4 (SAS Institute, Cary, NC, USA), with statistical significance set at p < 0.05 (two-sided test).

3. Results

At the time of analysis, a total of 8798 patients with mRCC were included in the overall IMDC data set. Within this population, 647 patients were identified as having papillary histology. Those who had a prior nephrectomy and then subsequently developed metastatic disease were excluded (n = 294) to isolate patients with synchronous metastatic disease. The final numbers for the analysis included 109 patients without CN and 244 with CN. The median number of patients included by the contributing institutions was nine. The median follow-up for all patients was 57.1 mo (95% confidence interval [CI] 32.9–77.8). The median OS from the start of first-line targeted therapy for the entire cohort was 13.2 mo (95% CI 12.0–16.1).

Table 1 compares baseline characteristics for the CN and no-CN groups. Table 2 summarizes the type of targeted therapy received and the number of subsequent lines of therapy. Patients who underwent CN were more likely to be younger (p = 0.0001) with better performance status (p = 0.0231). There was also a higher number of bone metastases in the CN group (p = 0.0281). The proportions of type 1 and type 2 histology were similar between the two groups (p = 0.902). Sunitinib was the most common first-line targeted therapy used in both groups. The ORR to first-line therapy did not differ between CN and no-CN (12% vs 5.9%; p = 0.2847).

The median OS for the CN group was 16.3 mo, compared to 8.6 mo in the no-CN group (Fig. 1; p < 0.0001). On multivariable analysis adjusted for IMDC prognostic factors, the HR for death was 0.62 (95% CI 0.45–0.85; p = 0.0031), translating into a 38% decrease in the risk of death with CN. After adjusting for additional prognostic imbalances including the IMDC criteria, age, and the presence of bone metastases, the HR improved to 0.55 (95% CI 0.39–0.78; p = 0.0006). With regard to secondary outcomes, PFS also appeared to be
prolonged in the CN group at 5.1 mo, compared to 3.4 mo in the no-CN group (Fig. 2; \( p = 0.0344 \)). After adjusting for the IMDC factors, the HR for PFS was 0.82 (95% CI 0.61–1.10; \( p = 0.1822 \)). When age and the presence of bone metastases were added to the regression model, the HR for PFS was 0.73 (95% CI 0.53–1.01; \( p = 0.0555 \)). For comparative purposes, we performed an analysis of CN versus no-CN in the ccRCC population. In this ccRCC subset, median OS was 21.8 mo in the CN group, compared to 10.0 mo in the no-CN group (\( p < 0.0001 \)).

We also performed a subgroup analysis by dividing the CN cohort into immediate systemic therapy (defined as within 90 d of surgery) and delayed systemic therapy (defined as >90 d from CN) groups. There was no significant survival difference between these two subgroups.

4. Discussion

The role of CN in the contemporary management of advanced kidney cancer has been well studied in retrospective studies, analyses of real-world data, and randomized controlled trials. Prior retrospective analyses of different data sets, including the IMDC and the National Cancer Data Base, have consistently revealed that CN appears to offer a survival benefit in ccRCC [5,10].

Although more limited than the literature on ccRCC, previous retrospective analyses have also suggested a benefit of CN in nccRCC [11,12]. It is important to note that nccRCC represents a diverse spectrum of pathological and clinical entities, with papillary RCC being the most common subtype. Aizer et al. [12] analyzed the role of CN in metastatic nccRCC using the Surveillance, Epidemiology, and End Results (SEER) database. In this more heterogeneous population, CN was associated with lower cancer-specific and all-cause mortality (HR 0.45, 95% CI 0.37–0.55; \( p < 0.001 \)). Marchioni et al. [11] also examined the role of CN in nccRCC patients using an updated analysis of the SEER database. They again demonstrated a cancer-specific mortality benefit with CN (HR 0.38, 95% CI 0.30–0.47; \( p < 0.001 \)). In a subgroup analysis looking at patients with papillary RCC, CN was also associated with better cancer-specific mortality (HR 0.40, 95% CI 0.30–0.53; \( p < 0.001 \)). None of these studies adjusted for potential confounders such as IMDC criteria, specifically for the time between diagnosis and systemic therapy.

The results of our analysis for patients with exclusively papillary RCC are consistent with these findings. In contrast to the SEER database, the IMDC is able to control for more specific prognostic variables, including performance status at initiation of systemic therapy and biochemical parameters. In our study, the group receiving CN were younger and had better performance status, probably reflecting an element of bias in surgical selection. We demonstrated that patients undergoing CN had significantly better OS, even when controlling for prognostic imbalances between these groups, including performance status, age, and the IMDC risk factors. A PFS benefit in favor of CN did not meet statistical significance in the multivariable analysis. The proportion of type 1 and type 2 histology was similar between these two groups, which is important given the clinical significance of these subtypes. To the best of our knowledge, our study represents the largest multivariable analysis exploring CN in papillary RCC. Given that advanced papillary RCC typically has
lower response rates to traditional VEGF targeted therapies, it may be even more important to achieve local tumor control and cytoreduction in this tumor subtype [13].

In contrast to these findings, the recently reported CARMENA randomized controlled trial demonstrated that sunitinib therapy alone appeared to be noninferior to CN followed by sunitinib in patients with intermediate and poor risk [6]. The results in the sunitinib-alone group were noninferior to those in the CN followed by sunitinib group with regard to OS (stratified HR for death, 0.89, 95% CI 0.71–1.10; upper bound of the 95% CI for noninferiority, ≤1.20).

Importantly, the CARMENA trial excluded patients with nccRCC and by definition excluded patients with favorable risk. In addition, patients randomized in this trial may not accurately reflect ideal CN candidates in a real-world setting, possibly because of a perceived lack of clinical equipoise [14]. This was evident in the slow accrual to the trial, which required a reduction in its sample size, and the unusually high number of IMDC poor-risk patients in the cohort (43%). Prior studies using the IMDC database have suggested that patients with poorer risk, including those with four or more IMDC risk factors, do not appear to derive benefit from CN [5]. Thus, utilization of CN in this poor-risk population may have helped the trial meet its noninferiority endpoint. The efficacy of systemic therapy in papillary RCC is suboptimal, highlighting the importance of CN as a potential therapeutic strategy in metastatic disease.

In general, CN may be considered for patients with good performance status and limited or slow-growing metastatic disease. Symptomatic patients with ongoing hematuria or flank pain may also benefit from CN. It is important to discuss these cases in a multidisciplinary tumor board to consider CN feasibility, comorbidities, and an estimate of the overall prognosis to gain an insight into whether the patients will benefit from surgery. Thus, for patients with papillary RCC, careful patient selection for CN is crucial.

Another randomized trial (SURTIME trial) randomized mRCC patients to immediate CN followed by sunitinib versus delayed CN after three cycles of initial sunitinib [15,16]. A trend towards better OS for those with deferred nephrectomy was observed. This may in part be due to patient selection after initial sunitinib, in that patients who had a favorable tumor response went on to CN, while CN was aborted for those who had progressive disease. This trial may give treating physicians the comfort that delaying a decision on CN may be reasonable, especially for patients with intermediate or poor risk. Similar to the CARMENA trial, SURTIME included patients with ccRCC only, and thus may not be fully generalizable to those with nccRCC or papillary histology.

Limitations of our study include the retrospective nature of the analysis and the presence of inherent, unmeasured confounders that could not be adjusted for, despite multivariable analysis. Selection bias is another important limitation that is intrinsic to the retrospective design of the study. The IMDC uses a consecutive patient series to minimize selection bias. Given these limitations, a causal relationship between CN and survival cannot be definitively established. There was no central pathology review, as this was a multi-institutional study. Our data set only includes patients who are receiving active systemic therapy, and thus does
not include patients with mRCC undergoing active surveillance. Owing to low patient numbers, we were unable to perform a subgroup analysis looking at the relationship between a number of individual IMDC factors and benefit from CN. We were also unable to account for outcomes such as perioperative mortality and surgery-related morbidity.

5. Conclusions

In summary, in our data set it appears that CN is associated with better survival in metastatic papillary RCC, even when controlling for known prognostic imbalances between the groups. Given the lower response rates to targeted therapy in papillary RCC, achieving local tumor control may be particularly important in this pathological subtype. As in the more commonly studied ccRCC population, selection of patients for CN will be critical. Unfortunately, a prospective clinical trial in this rare subgroup may not be possible. As the treatment landscape for mRCC evolves, it will be important to reevaluate the role of CN in papillary RCC, particularly in combination with novel IO and MET targeted therapy.

Acknowledgments

Funding/Support and role of the sponsor: None.

Financial disclosures: Daniel Y.C. Heng certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Jae Lyun Lee has received honoraria from Astellas Pharma, Bristol-Myers Squibb, Novartis, and Pfizer; has acted in a consulting or advisory role for Astellas Pharma, AstraZeneca, and Eisai; and has received research funding from Bristol-Myers Squibb, Exelixis, Janssen, Novartis, Pfizer, and Roche/Genentech. Camillo Porta has acted in a consulting or advisory role for Bristol-Myers Squibb, Eisai, EUSA Pharma, Ipsen, Janssen, Novartis, Pfizer, Roche Canada, and Sanofi Canada; and has received institutional research funding from Merck and Pfizer; and has received travel and accommodation expenses from Novartis and Pfizer. D. Scott Ernst has acted in a consulting or advisory role for AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, Novartis Canada Pharmaceuticals, and Roche Canada. Benoit Benselinck has received honoraria from Amgen, Bayer, Janssen, and Pfizer. Scott A. North has received honoraria from Astellas Pharma, Janssen-Ortho, Novartis, Pfizer, and Sanofi Canada; has acted in a consulting or advisory role for Astellas Pharma, AstraZeneca, Janssen Oncology, Merck, Novartis, Pfizer, Roche Canada, and Sanofi Canada; and has received institutional research funding from Astellas Pharma, AstraZeneca, Janssen, Novartis Canada Pharmaceuticals, Roche Canada, and Sanofi Canada. Christian K. Kollmannsberger has received honoraria from Bristol-Myers Squibb, Novartis, and Pfizer; has acted in a consulting or advisory role for Astellas Pharma, Bristol-Myers Squibb, Merck, Novartis Canada Pharmaceuticals, and Seattle Genetics; and has received travel and accommodation expenses from Novartis and Pfizer. Lori A. Wood has received institutional research funding from Aragon Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Exelixis, Merck, Novartis, Pfizer, and Roche Canada. Ulka N. Vaishampayan has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech/Roche, and Pfizer; and has received research funding from Astellas Pharma, Bristol-Myers Squibb, Exelixis, Novartis, and Pfizer. Sumanta K. Pal has received honoraria from Astellas Pharma, Medivation, and Novartis; has acted in a consulting or advisory role for Astellas Pharma, Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Ipsen, Myriad Pharmaceuticals, Novartis, and Pfizer; and has received research funding from Medivation. Toni K. Choueiri has received honoraria from NCCN and UpToDate; has acted in a consulting or advisory role for Alligent, AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Exelixis, Foundation Medicine, GlaxoSmithKline, Merck, Novartis, Pfizer, Prometheus Laboratories, and Roche/Genentech; has received institutional research funding from Agensys, AstraZeneca, Bristol-Myers Squibb, Celldex, Exelixis, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche/Genentech, and TRACON Pharma; and has received travel and accommodation expenses when acting in an advisory or consulting role. Daniel Y.C. Heng has acted in a consulting or advisory role for Astellas Pharma, Bristol-Myers Squibb, Janssen, Novartis, and Pfizer; and has received institutional research funding from Bristol-Myers Squibb, Exelixis, Novartis, and Pfizer. The remaining authors have nothing to disclose.
References


Fig. 1 –. Kaplan-Meier curve for overall survival (OS) for the CN and no-CN groups. CN = cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium.

1 Adjusted for IMDC prognostic factors.
2 Adjusted for IMDC prognostic factors, age, and bone metastases.
Fig. 2 –.
Kaplan-Meier curve for progression-free survival (PFS) for the CN and no-CN groups. CN = cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium.
1 Adjusted for IMDC prognostic factors.
2 Adjusted for IMDC prognostic factors, age, and bone metastases.
<table>
<thead>
<tr>
<th></th>
<th>No CN (N = 109)</th>
<th>CN (N = 244)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>86/109 (79)</td>
<td>173/244 (71)</td>
<td>0.1163</td>
</tr>
<tr>
<td>Median age (yr)</td>
<td>67</td>
<td>59</td>
<td>0.0001</td>
</tr>
<tr>
<td>Karnofsky performance status &lt;80%, n/N (%)</td>
<td>28/90 (31)</td>
<td>41/214 (19)</td>
<td>0.0231</td>
</tr>
<tr>
<td>Diagnosis to targeted therapy &lt;1 yr, n/N (%)</td>
<td>99/109 (91)</td>
<td>204/244 (84)</td>
<td>0.0723</td>
</tr>
<tr>
<td>Calcium &gt;ULN, n/N (%)</td>
<td>16/89 (18)</td>
<td>30/193 (16)</td>
<td>0.6072</td>
</tr>
<tr>
<td>Hemoglobin &lt;LLN, n/N (%)</td>
<td>69/99 (70)</td>
<td>136/216 (63)</td>
<td>0.2445</td>
</tr>
<tr>
<td>Neutrophils &gt;ULN, n/N (%)</td>
<td>25/98 (26)</td>
<td>38/209 (18)</td>
<td>0.1383</td>
</tr>
<tr>
<td>Platelets &gt;ULN, n/N (%)</td>
<td>26/98 (27)</td>
<td>42/213 (20)</td>
<td>0.1769</td>
</tr>
<tr>
<td>Histologic subtype, n/N (%)</td>
<td>0.902</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 1</td>
<td>6/41 (14.6)</td>
<td>13/94 (13.8)</td>
<td></td>
</tr>
<tr>
<td>Type 2</td>
<td>35/41 (85.4)</td>
<td>81/94 (86.2)</td>
<td></td>
</tr>
<tr>
<td>Liver metastases, n/N (%)</td>
<td>21/105 (20)</td>
<td>50/207 (24%)</td>
<td>0.4082</td>
</tr>
<tr>
<td>Bone metastases, n/N (%)</td>
<td>30/107 (28)</td>
<td>86/212 (41%)</td>
<td>0.0281</td>
</tr>
<tr>
<td>Brain metastases, n/N (%)</td>
<td>3/106 (2.8)</td>
<td>5/204 (2.5%)</td>
<td>0.8417</td>
</tr>
<tr>
<td>More than one site of metastasis, n/N (%)</td>
<td>87/108 (81)</td>
<td>169/222 (76.1%)</td>
<td>0.3653</td>
</tr>
<tr>
<td>IMDC risk group, n/N (%)</td>
<td>0.2627</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable risk</td>
<td>4/78 (5.1)</td>
<td>10/175 (5.7)</td>
<td></td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>37/78 (47)</td>
<td>101/175 (58)</td>
<td></td>
</tr>
<tr>
<td>Poor risk</td>
<td>37/78 (47)</td>
<td>64/175 (37)</td>
<td></td>
</tr>
</tbody>
</table>

CN = cytoreductive nephrectomy; ULN = upper limit of normal; LLN = lower limit of normal; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium.
Table 2 –
Baseline treatment characteristics for the CN and no-CN groups.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No CN (N = 109)</th>
<th>CN (N = 244)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td>59/109 (54)</td>
<td>134/244 (55)</td>
<td></td>
</tr>
<tr>
<td>Sorafenib</td>
<td>3/109 (2.8)</td>
<td>31/244 (13)</td>
<td></td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>25/109 (23)</td>
<td>31/244 (13)</td>
<td></td>
</tr>
<tr>
<td>Pazopanib</td>
<td>12/109 (11)</td>
<td>19/244 (7.8)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>10/109 (9.1)</td>
<td>29/244 (12)</td>
<td></td>
</tr>
<tr>
<td>Second-line therapy</td>
<td>43/109 (39)</td>
<td>137/244 (56)</td>
<td>0.0037</td>
</tr>
<tr>
<td>Third-line therapy</td>
<td>17/109 (16)</td>
<td>58/244 (24)</td>
<td>0.0828</td>
</tr>
<tr>
<td>Fourth-line therapy</td>
<td>4/109 (3.7)</td>
<td>16/244 (6.6)</td>
<td>0.2783</td>
</tr>
</tbody>
</table>

CN = cytoreductive nephrectomy.